Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.47 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313490 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8184231 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL749253 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8184232 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8928824 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL9164604 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8928920 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11418144 | 0.96 | NT5E (0.93) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11418140 | 0.96 | NT5E (0.93) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL21749232 | 0.91 | NT5E (0.84) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
| US-6093698-A | 1-(2',3',5'-TRIACETYL-BETA-D-RIBOFURANOSYL),2-BROMO,5,6-DICHLORO -BENZIMIDAZOLE OR 1-(5'-ACETYL-BETA-D-RIBOFURANOSYL),2-BROMO,5,6-DICHLORO-BENZIMIDAZOLE; TREATING HERPES VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0670845-B1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AG (DE) | 1998-01-14 | — | — | EP | disclosed |
| US-5705490-A | TREATMENT OF HERPES OR CYTOMEGALOVIRUS WITH BENZIMIDAZOLE DERIATIVES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-01-06 | — | — | US | disclosed |
| US-5668270-A | Process for the preparation of fludarabine or fludarabine phosphate from guanosine | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-16 | — | — | US | disclosed |
| US-5654283-A | HERPES VIRUS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646125-A | Polysubstituted benzimidazoles as antiviral agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-07-08 | — | — | US | disclosed |
| US-5602246-A | Process for the preparation of fludarabine or fludarabine phosphate from guanosine | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5574058-A | Polysubstituted benzimidazoles as antiviral agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0670845-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | disclosed |
| US-5360795-A | Treating cytomegalo virus and herpes simplex viruses | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1994012514-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-06-09 | — | — | WO | disclosed |
| WO-1994008456-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5180824-A | 6-AZIDO-2-FLUOROPURINE, USEFUL IN THE SYNTHESIS OF NUCLEOSIDES | BERLEX BIOSCIENCES INC. (US) | 1993-01-19 | — | — | US | disclosed |
| US-4210745-A | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | NT5E 49/4885PTPN1 2590/4885CDC25B 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.